• Reme-D closed a $1.45 million Pre-Series A led by Anara Impact Capital, with Global Innovation Fund and Africa Health Ventures also participating.
• The round follows a $500,000 check from Global Innovation Fund in April 2026, putting disclosed funding at roughly $1.95 million to date.
• Proceeds fund a move to a 1,500 sqm facility and a tenfold increase in manufacturing capacity, plus new diagnostics for genetic disease and cancer.
• Since founding in 2023, the team grew from five to fifty people and shipped over 550,000 tests across Egypt, Kenya, and Sudan.
• The bet is that locally manufactured molecular diagnostics for TB, HIV, hepatitis, and HPV can undercut imported tests on cost and heat-resilience for underserved markets.

Reme-D, a Cairo-based molecular diagnostics manufacturer, has raised $1.45 million in a Pre-Series A round led by Anara Impact Capital, with Global Innovation Fund and Africa Health Ventures participating, Wamda reported. The money is earmarked for a specific, measurable move: a 1,500 square meter facility that the company says will lift manufacturing capacity roughly tenfold. That bet rests on three years of shipped volume — more than 550,000 tests across Egypt, Kenya, and Sudan — not a forecast.

The number behind the round: five people to fifty

Reme-D started in 2023 with five people building molecular diagnostic tests in Cairo. Three years later the team is fifty, the product line runs to 30 commercialized diagnostics, and more than 550,000 tests have shipped across Egypt, Kenya, and Sudan, according to Wamda. That headcount and shipment growth, not a pitch deck narrative, is what Anara Impact Capital priced when it led the $1.45 million Pre-Series A. Investors backing hardware-adjacent health manufacturing want proof of repeat orders before capacity spend — Reme-D had it.

Where the money goes: a tenfold capacity jump

The round funds a move to a 1,500 square meter facility, which Reme-D says raises manufacturing capacity roughly tenfold. That is a capital-intensive bet for a $1.45 million check, which suggests the round covers a down payment on equipment and lease rather than the full build-out — a distinction Reme-D has not itemized publicly. The company is also directing funds toward new diagnostics for genetic diseases and cancer, moving beyond its current TB, HIV, hepatitis, and HPV panel, and toward expanding its regional footprint beyond the three countries it already serves.

The stack of investors and what each one signals

Anara Impact Capital led the round; the Global Innovation Fund and Africa Health Ventures participated, alongside unnamed other investors, Wamda reported. Global Innovation Fund is a repeat backer — it put in $500,000 in April 2026, months before this larger round closed, suggesting the earlier check bought enough diligence runway to justify writing again. Mohamed Hussain of Anara Impact Capital said Reme-D demonstrated that high-quality molecular diagnostics can be developed and manufactured locally, per Wamda — the framing an impact investor uses when the thesis is import substitution, not just clinical accuracy.

The proof point that predates the funding: a WHO deployment

Before this round, Reme-D equipped a solar-powered mobile laboratory for WHO Egypt to monitor vector-borne diseases, a deployment that functions as a reference customer more persuasive than any projection. Founder Salma Tammam framed the company's goal as patients across Africa and the Global South accessing advanced molecular tests without cost or availability barriers, per Wamda. Temperature-resilient, locally made diagnostics matter specifically where cold-chain logistics for imported tests break down — the WHO mobile-lab deployment is the operational evidence for that claim, not a marketing line.

The bet

Reme-D is betting that a tenfold jump in manufacturing capacity converts existing demand — 550,000 tests already sold across three countries — into a defensible regional supply position before a larger, better-capitalized diagnostics maker moves in on the same underserved markets. The round is small relative to the capacity ambition, which means the next disclosed raise, and whether Global Innovation Fund writes a third check, will tell us whether this factory move actually shipped on schedule.